Prevalence of Patients With Nonmetastatic Prostate Cancer on Androgen Deprivation Therapy in the United States
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United StatesPharmacoepidemiology and Drug Safety, 2011
- Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United StatesUrologic Oncology: Seminars and Original Investigations, 2011
- Reimbursement Policy and Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyThe Lancet Oncology, 2006
- Androgen Deprivation Therapy for Prostate CancerJAMA, 2005
- Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinomaCancer, 2005
- 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate CancerJAMA, 2004
- The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinomaCancer, 2002
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialThe Lancet, 2002